You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)全球創新藥STC3141獲批進入COVID-19ARDSII期和膿毒症Ib期臨牀研究
格隆匯 05-06 19:06

格隆匯5月6日丨遠大醫藥(00512.HK)發佈公告,集團全資擁有附屬公司 Grand Medical Pty Ltd(一間集團在澳洲設立的創新藥研發中心)正在開發的用於治療膿毒症的全球創新藥物 STC3141,日前已分別獲得批准在澳洲開展用於治療感染 2019 冠狀病毒病(COVID-19)患者的急性呼吸窘迫綜合症(ARDS)(COVID-19 ARDS」)的 II 期臨牀研究和用於治療膿毒症的 Ib 期臨牀研究。

STC3141 已在澳洲完成了健康志願者的 Ia 期臨牀研究,初步確定了藥物的人體安全性及代謝特性。此次 COVID-19 ARDS 的 II 期臨牀研究將在重症監護室對 COVID-19 的重症患者進行,以研究和評估藥物對於治療 COVID-19 患者的 ARDS 的安全性和有效性。而膿毒症的 Ib 期臨牀研究將進一步評估藥物在膿毒症患者中的安全性及代謝特性。

獲批進行膿毒症 Ib 期臨牀研究確保了 STC3141 的膿毒症適應症的開發按計劃進行,同時 COVID-19 ARDS 的 II 期臨牀研究使得 STC3141 有望在 COVID-19 ARDS 治療領域中成為全球研發進度最快的創新候選藥物之一,將有助於加快該產品應對多適應症的全球開發速度,力爭惠及更多患者及為全球疫情防控貢獻力量。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account